选择性PI3K抑制剂的研究进展

被引:14
作者
吴成军
赵金龙
周志旭
杜磊
柳蓓蓓
孙铁民
机构
[1] 沈阳药科大学创新药物研究与设计教育部重点实验室
关键词
磷脂酰肌醇3-激酶; 选择性PI3K抑制剂; 抗肿瘤;
D O I
暂无
中图分类号
R730.5 [肿瘤治疗学];
学科分类号
100214 [肿瘤学];
摘要
磷脂酰肌醇3-激酶(PI3K)是细胞内重要的信号转导分子,在细胞存活、增殖和分化过程中起重要调节作用。PI3K是PI3K/AKT/mT0R信号转导通路中的关键节点蛋白,调控着重要的生命活动。现已证实磷脂酰肌醇3-激酶(PI3Ks)是潜力巨大的药物治疗靶点,特别是PI3Kα现己成为抗肿瘤治疗的重要靶点之一。目前己有多种针对PI3Ks的抑制剂进入临床研究。然而现有抑制剂的化学类型不多且选择性不高、临床应用受局限。因此积极研究和开发结构新颖的PI3K选择性抑制剂对于疾病的靶向治疗具有重要意义。本文将对选择性PI3K抑制剂在抗肿瘤方面的研究进展作一综述。
引用
收藏
页码:305 / 310+384 +384
页数:7
相关论文
共 12 条
[1]
抗癌药物磷脂酰肌醇3激酶抑制剂 [J].
王宇驰 ;
姚瑜 .
国外医药(抗生素分册), 2008, (05) :206-212
[2]
靶向PI3K-Akt-mTOR信号通路抑制剂的研究进展 [J].
张超 ;
杨娜 ;
章雄文 ;
丁健 .
中国癌症杂志, 2006, (12) :1064-1070
[3]
Combination of the PI3K Inhibitor ZSTK474 with a PSMA-Targeted Immunotoxin Accelerates Apoptosis and Regression of Prostate Cancer [J].
Baiz, Daniele ;
Hassan, Sazzad ;
Choi, Young A. ;
Flores, Anabel ;
Karpova, Yelena ;
Yancey, Dana ;
Pullikuth, Ashok ;
Sui, Guangchao ;
Sadelain, Michel ;
Debinski, Waldemar ;
Kulik, George .
NEOPLASIA, 2013, 15 (10) :1158-1169
[4]
Multimodal Microvascular Imaging Reveals that Selective Inhibition of Class I PI3K Is Sufficient to Induce an Antivascular Response [J].
Sampath, Deepak ;
Oeh, Jason ;
Wyatt, Shelby K. ;
Cao, Tim C. ;
Koeppen, Hartmut ;
Eastham-Anderson, Jeffrey ;
Robillard, Liliane ;
Ho, Calvin C. K. ;
Ross, Jed ;
Zhuang, Guanglei ;
Reslan, Hani Bou ;
Vitorino, Philip ;
Barck, Kai H. ;
Ungersma, Sharon E. ;
Vernes, Jean Michel ;
Caunt, Maresa ;
Van Bruggen, Nick ;
Ye, Weilan ;
Vijapurkar, Ulka ;
Meng, Yu-Ju Gloria ;
Ferrara, Napoleone ;
Friedman, Lori S. ;
Carano, Richard A. D. .
NEOPLASIA, 2013, 15 (07) :694-+
[5]
PI3K Inhibitors as Novel Cancer Therapies: Implications for Cardiovascular Medicine [J].
Mclean, Brent A. ;
Zhabyeyev, Pavel ;
Pituskin, Edith ;
Paterson, Ian ;
Haykowsky, Mark J. ;
Oudit, Gavin Y. .
JOURNAL OF CARDIAC FAILURE, 2013, 19 (04) :268-282
[6]
Challenges in the clinical development of PI3K inhibitors.[J].Cristian Massacesi;Emmanuelle Tomaso;Nathalie Fretault;Samit Hirawat.Ann. N.Y. Acad. Sci..2013, 1
[7]
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.[J].Yuhuan Zheng;Jing Yang;Jianfei Qian;Liang Zhang;Yong Lu;Haiyan Li;Heather Lin;Yongsheng Lan;Zhiqiang Liu;Jin He;Sungyoul Hong;Sheeba Thomas;Jatin Shah;Veera Baladandayuthapani;Larry Kwak;Qing Yi.Journal of Molecular Medicine.2012, 6
[8]
Chemical Synthesis of Ubiquitinated Peptides with Varying Lengths and Types of Ubiquitin Chains to Explore the Activity of Deubiquitinases [J].
Bavikar, Sudhir N. ;
Spasser, Liat ;
Haj-Yahya, Mahmood ;
Karthikeyan, Subramanian Vedhanarayanan ;
Moyal, Tal ;
Kumar, K. S. Ajish ;
Brik, Ashraf .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2012, 51 (03) :758-763
[9]
Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799 [J].
Ohwada, Jun ;
Ebiike, Hirosato ;
Kawada, Hatsuo ;
Tsukazaki, Masao ;
Nakamura, Mitsuaki ;
Miyazaki, Takuya ;
Morikami, Kenji ;
Yoshinari, Kiyoshi ;
Yoshida, Miyuki ;
Kondoh, Osamu ;
Kuramoto, Shino ;
Ogawa, Kotaro ;
Aoki, Yuko ;
Shimma, Nobuo .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (06) :1767-1772
[10]
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy [J].
Ihle, Nathan T. ;
Powis, Garth .
MOLECULAR ASPECTS OF MEDICINE, 2010, 31 (02) :135-144